Products
Pinatuzumab Biosimilar Antibody-Drug Conjugate (CD22) for Research
Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pinatuzumab vedotin (DCDT2980S, FCU2703) is an anti-CD22 antibody-drug conjugate (ADC) developed by Genentech/ Hoffmann-La Roche for the treatment of diffuse large B-cell lymphoma (DLBCL). ... Pinatuzumab vedotin has proved its efficacy in inducing a complete tumor regression in xenograft lymphoma models.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-444-1mg | 1mg | 4635 |
| GMP-Bios-ab-444-10mg | 10mg | |
| GMP-Bios-ab-444-100mg | 100mg | |
| GMP-Bios-ab-444-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
| INN Name | Pinatuzumab |
| Target | CD22 |
| Format | Whole mAb ADC |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 6and:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma |
| Development Tech | na |
About target - CD22
1. Protein B-cell receptor CD22
2. Gene CD22
3. Organism Homo sapiens (Human)
Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Miscellaneous
In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Catalytic activity
Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
